

氏名	所属	職名	取得学位	専門分野	主な論文・著作・業績
西谷 直之	臨床薬学講座 情報薬科学分野	教授	博士（薬学）	創薬科学 腫瘍治療学 ケミカルバイオロジー	<p>①Katagiri, H., Yonezawa, H., Shitamura, S., Sugawara, A., Kawano, T., Maemondo, M., Nishiya, N. : A Wnt/β-catenin signaling inhibitor, IMU1003, suppresses the emergence of osimertinib-resistant colonies from gefitinib-resistant non-small cell lung cancer cells./ <i>Biochem Biophys Res Commun.</i> 645:24-29 (2023)</p> <p>②Yonezawa, H., Ikeda, A., Takahashi, R., Endo, H., Sugawara, Y., Goto, M., Kanno, M., Ogawa, S., Nakamura, K., Ujii, H., Iwatsuki, M., Hirose, T., Sunazuka, T., Uehara, Y., Nishiya, N. : Ivermectin represses Wnt/β-catenin signaling by binding to TELO2, a regulator of phosphatidylinositol 3-kinase-related kinases./ <i>iScience.</i> 25(3):103912 (2022)</p> <p>③Nishiya, N., Oku, Y., Ishikawa, C., Fukuda, T., Dan, S., Mashima, T., Ushijima, M., Furukawa, Y., Sasaki, Y., Otsu, K., Sakyo, T., Abe, M., Yonezawa, H., Ishibashi, F., Matsuura, M., Tomida, A., Seimiya, H., Yamori, T., Iwao, M., Uehara, Y. : Lamellarin 14, a Derivative of Marine Alkaloids, Inhibits the T790M/C797S Mutant Epidermal Growth Factor Receptor. / <i>Cancer Sci.</i>, 112: 1963–1974 (2021)</p> <p>④文部科学省科学研究費補助金「課題名：mTORC構成因子Tel2を標的とする新規マクロライド系Wnt経路阻害薬の開発」2021～2023年</p> <p>⑤特許 第7090252号「第四世代EGFRチロシンキナーゼ阻害剤」令和4年6月16日</p>
佐京 智子	臨床薬学講座 情報薬科学分野	助教	博士（医学）	細胞生物学 病態医化学 腫瘍生物学	<p>①Nishiya, N., Oku, Y., Ishikawa, C., Fukuda, T., Dan, S., Mashima, T., Ushijima, M., Furukawa, Y., Sasaki, Y., Otsu, K., Sakyo, T., Abe, M., Yonezawa, H., Ishibashi, F., Matsuura, M., Tomida, A., Seimiya, H., Yamori, T., Iwao, M., Uehara, Y. : Lamellarin 14, a Derivative of Marine Alkaloids, Inhibits the T790M/C797S Mutant Epidermal Growth Factor Receptor. / <i>Cancer Sci.</i>, 112: 1963–1974 (2021)</p> <p>②Yonezawa, H., Sugawara, A., Sakyo, T., Uehara, Y., Kawano, T., Nishiya, N. : IMU1003, an atrarate derivative, inhibits Wnt/β-catenin signaling. / <i>Biochem. Biophys. Res. Commun.</i> 532: 440-445 (2020)</p> <p>③Watanabe, M., Naraba, H., Sakyo, T., Kitagawa, T. : DNA damage-induced modulation of GLUT3 expression is mediated through p53-independent extracellular signal-regulated kinase signaling in HeLa cells. / <i>Mol Cancer Res.</i>8, 1547-57 (2010)</p> <p>④Sakyo, T., Naraba, H., Teraoka, H., and Kitagawa, T. : The intrinsic structure of glucose transporter isoforms Glut1 and Glut3 regulates their differential distribution to detergent-resistant membrane domains in non-polarized mammalian cells. / <i>FEBS Journal</i>, vol. 274, 2843-2853 (2007)</p> <p>⑤Sakyo, T., and Kitagawa, T. : Differential localization of glucose transporter isoforms in non-polarized mammalian cells: Distribution of GLUT1 but not GLUT3 to detergent-resistant membrane domains. / <i>Biochimica Biophysica Acta(BBA)-Biomembranes</i>, 1567: 165-175 (2002)</p>

氏家 悠貴	臨床薬学講座 情報薬科学分野	助教	学士 (薬学)	医療薬学 がん化学療法	<p>①氏家悠貴 (著者) ,中原保裕 (監修) ,今日の臨床サポート,がん免疫療法 (薬理) ,エルゼビア・ジャパン(2023) https://clinicalsup.jp/jpoc/contentpage.aspx?diseaseid=2283.</p> <p>②Yonezawa, H., Ikeda, A., Takahashi, R., Endo, H., Sugawara, Y., Goto, M., Kanno, M., Ogawa, S., Nakamura, K., Ujiie, H., Iwatsuki, M., Hirose, T., Sunazuka, T., Uehara, Y., Nishiya, N. : Ivermectin represses Wnt/β-catenin signaling by binding to TELO2, a regulator of phosphatidylinositol 3-kinase-related kinases. / iScience. 7;25:103912(2022).</p> <p>③Ujiie, H., Nihei, S., Nishiya, N., Goto, S., Asakura, Y., Miura, S., Hirai, D., Endo, M., Oyake, T., Ito, S., Chiba, T., Kudo, K. : Switching from Intravenous to Oral Tacrolimus Reduces its Blood Concentration in Paediatric Cancer Patients. / Anticancer Res. 41:2591-2596 (2021)</p> <p>④Takahashi, H., Asaka, J., Tairabune, T., Ujiie, H., Matsuura, Y., Nihei, S., Kimura, T., Chiba, T., Kudo K. : Analysis of risk factors for skin disorders caused by anti-epidermal growth factor receptor antibody drugs and examination of methods for their avoidance. / J Clin Pharm Ther, Online ahead of print. doi: 10.1111/jcpt.13475. (2021)</p> <p>⑤Oku, Y., Tareyanagi, C., Takaya, S., Osaka, S., Ujiie, H., Yoshida, K., Nishiya, N., Uehara, Y. : Multimodal Effects of Small Molecule ROCK and LIMK Inhibitors on Mitosis, and Their Implication as Anti-Leukemia Agents. / PLoS One, 9:e92402. (2014)</p>
-------	-------------------	----	---------	----------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------